Menu
Back to Journals » Diabetes, Metabolic Syndrome and Obesity » Volume 17
Clinical Characteristics and Major Adverse Cardiovascular Events in Diabetic and Non-Diabetic Patients with Vasospastic Angina [Response to Letter]
Authors Teragawa H , Uchimura Y, Oshita C, Hashimoto Y, Nomura S
Received 9 October 2024
Accepted for publication 21 October 2024
Published 25 October 2024 Volume 2024:17 Pages 3989—3990
Hiroki Teragawa, Yuko Uchimura, Chikage Oshita, Yu Hashimoto, Shuichi Nomura
Department of Cardiovascular Medicine, JR Hiroshima Hospital, Hiroshima, Japan
Correspondence: Hiroki Teragawa, Department of Cardiovascular Medicine, JR Hiroshima Hospital, 3-1-36 Futabanosato, Higashi-ku, Hiroshima, 732-0057, Japan, Tel +81 82 262 1171, Fax +81 82 262 1499, Email [email protected]
xView the original paper by Dr Teragawa and colleagues
This is in response to the Letter to the Editor
Dear editor
In our recently published paper,1 we received a letter from Dr. Song2 asking about the influence of diabetes mellitus (DM) on the prognosis of patients with vasospastic angina (VSA). To the best of our knowledge, we have responded to his inquiries herein. We would like to thank him for taking the time to read our material.
We retrospectively examined the clinical background and effect of the presence of DM in patients with VSA. The presence of DM was associated with a higher incidence of atherosclerotic lesions on coronary angiography (CAG) but a lower tendency of incidence of focal spasms. In terms of prognosis, the presence of DM did not affect the incidence of major adverse cardiovascular events (MACE) overall; however, in the focal spasm group, the presence of DM was associated with a higher incidence of MACE.
Song suggested that although focal spasms affect the prognosis, many other factors affect the prognosis of VSA,2 and a comprehensive analysis of these factors is warranted. Furthermore, they proposed taking into account the control status of DM and disease duration, as these may also affect the frequency of MACE.3
As Song pointed out,2 several factors that have also been identified, such as smoking and other coronary risk factors, history of out-of-hospital cardiac arrest or presence of variant angina, use of beta-blockers, nonuse of calcium channel blockers, and specific findings on coronary angiography, such as significant stenosis, or on spasm provocation test, such as focal spasms and multivessel spasm.4–10 In addition to focal spasms as the focus of this study, many other factors have been identified to affect prognosis. Furthermore, in the prognosis of DM, considering the prognosis while taking into account the state of control of DM and the drugs used is desirable.3 Unfortunately, the abovementioned analysis was not possible in this study given the retrospective design, single-center setting, limited number of cases, and insufficient follow-up. To evaluate the effect of diabetes on coronary spasm, particularly focal spasms, while considering other risk factors and the state of blood glucose control, further evaluation in a prospective, multicenter registry is warranted.
Again, we deeply appreciate his interest in our paper on the prognostic influence of diabetes on VSA and his constructive suggestions.
Disclosure
The authors report no conflicts of interest in this communication.
References
1. Teragawa H, Uchimura Y, Oshita C, et al. Clinical characteristics and major adverse cardiovascular events in diabetic and non-diabetic patients with vasospastic angina. Diabetes Metab Syndr Obes. 2024;17:2135–2146. doi:10.2147/DMSO.S462234
2. Song Y. Clinical characteristics and major adverse cardiovascular events in diabetic and non-diabetic patients with vasospastic angina [Letter]. Diabetes Metab Syndr Obes. 2024;17:3725–3726. doi:10.2147/DMSO.S497353
3. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65(12):1925–1966. doi:10.1007/s00125-022-05787-2
4. Yasue H, Takizawa A, Nagao M, et al. Long-term prognosis for patients with variant angina and influential factors. Circulation. 1988;78(1):1–9. doi:10.1161/01.CIR.78.1.1
5. Group JCSJW. Guidelines for diagnosis and treatment of patients with vasospastic angina (coronary spastic angina) (JCS 2013). Circ J. 2014;78(11):2779–2801. doi:10.1253/circj.cj-66-0098
6. Takagi Y, Takahashi J, Yasuda S, et al. Prognostic stratification of patients with vasospastic angina: a comprehensive clinical risk score developed by the Japanese coronary spasm association. J Am Coll Cardiol. 2013;62(13):1144–1153. doi:10.1016/j.jacc.2013.07.018
7. Sato K, Kaikita K, Nakayama N, et al. Coronary vasomotor response to intracoronary acetylcholine injection, clinical features, and long-term prognosis in 873 consecutive patients with coronary spasm: analysis of a single-center study over 20 years. J Am Heart Assoc. 2013;2(4):e000227. doi:10.1161/JAHA.113.000227
8. Ishii M, Kaikita K, Sato K, et al. Acetylcholine-provoked coronary spasm at site of significant organic stenosis predicts poor prognosis in patients with coronary vasospastic angina. J Am Coll Cardiol. 2015;66(10):1105–1115. doi:10.1016/j.jacc.2015.06.1324
9. Nishimiya K, Suda A, Fukui K, et al. Prognostic links between OCT-delineated coronary morphologies and coronary functional abnormalities in patients with INOCA. JACC: Cardiovasc Interv. 2021;14(6):606–618. doi:10.1016/j.jcin.2020.12.025
10. Hokimoto S, Kaikita K, Yasuda S, et al. JCS/CVIT/JCC 2023 guideline focused update on diagnosis and treatment of vasospastic angina (coronary spastic angina) and coronary microvascular dysfunction. Circ J. 2023;87(6):879–936. doi:10.1253/circj.CJ-22-0779
© 2024 The Author(s). This work is published and licensed by Dove Medical Press Limited. The
full terms of this license are available at https://www.dovepress.com/terms.php
and incorporate the Creative Commons Attribution
- Non Commercial (unported, 3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted
without any further permission from Dove Medical Press Limited, provided the work is properly
attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.